ESR1 and breast cancer: Interestingly, GSIs proved ineffective against in triple negative (ER, PgR and HER-2) breast cancer, which displayed elevated Notch signaling, emphasizing the unique complexity of CSCs and tumor types (Meisel et al., 2020).